Method of preventing vertical transmission of hepatitis b and c viruses in pregnant women with reactivation of viruses in third trimester. RU patent 2473341.

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to infectious diseases and obstetrics, and can be used for prevention of vertical transmission of hepatitis B and C viruses in pregnant women. For this purpose in pregnant women with term of pregnancy from 28 to 30 weeks with reactivation of chronic viral hepatitis B and C, level of viral load is determined and if its value is higher than 10⁵ copies/ml, preparation Kipferon is introduced in dose 2 suppositories 2 times per day rectally with 12 hour interval during 14 days, and starting from 36 weeks of pregnancy repeated course is carried out in accordance with the same scheme.

EFFECT: method ensures correction of cell immunodeficiency, reduction of viremia level, prevention of vertical transmission of hepatitis B and C viruses in the third trimester of pregnancy to the moment of labour.

7 tbl, 2 ex

IPC classes for russian patent Method of preventing vertical transmission of hepatitis b and c viruses in pregnant women with reactivation of viruses in third trimester. RU patent 2473341. (RU 2473341):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K31/21 - Esters, e.g. nitroglycerine, selenocyanates

Another patents in same IPC classes:

Method of treating non-alcoholic steatohepatitis with application of dalargin magnetophoresis / 2473325
Invention relates to medicine, gastroenterology. Method includes dietotherapy in accordance with diet No 5, exercise therapy. Additionally intake of low-mineralised carbonaceous chloride-hydrocarbonate-sulfate-sodium-calcium mineral water "Essentuki-Novaya" is realised. Water is taken in in dose 3.5 ml per 1 kg of patient's body weight, 3 times per day, 30-40 minutes before meal. Carbonaceous-hydrogen sulfide mineral baths with content of hydrogen sulfide 15-20 mg/l are carried out every second day. Baths are taken with water temperature 36-37°C. Course includes 8-10 procedures. Dalargin magnetophoresis on liver projection is performed daily. Pulsing travelling magnetic field from apparatus AMO-ATOS is used. Magnetophoresis is carried out with induction 45 mT, with modulation frequency 10 Hz for 15 minutes, course includes 10 procedures.

Agent normalising liver mitochondria / 2470655
Invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Method of treating allergy, method of treating asthma, method of reducing risk of developing infection, and method of treating condition characterised by cytokine type 1 and 2 content imbalance by β-hydroxy-β-methylbutyrate / 2469719
For the purpose of treating allergy in an individual characterised by cytokine Th1 and Th2 imbalance, β-hydroxy-β-methylbutyrate (HMB) is introduced into the individual in an amount effective to reduce cytokine Th1 and Th2 production imbalance. What is also presented is a method of treating allergy in the individual belonging to a risk group of developing allergy.

(3r,4r,5s)-4-acylamino-5-amino-3-(1-ethyl-propoxy)-cyclohex-1-ene-carboxylic acids, their esters and method for using / 2469020
Invention refers to new substituted (3R,4R,5S)-5-amino-4-acylamino-3-(1-ethyl-propoxy)-cyclohex-1-ene carboxylic acids of general formula 1, their esters, pharmaceutically acceptable salts and/or hydrates possessing antiviral activity associated with inhibition of neuraminidase, particularly influenza virus neuraminidase. The invention also refers to pharmaceutical compositions and a based drug preparation, a method for inhibition of neuraminidase, and a method of treating influenza and pneumonia caused by influenza virus. In general formula 1 R1 represents hydrogen, C1-C7alkyl, C2-C7alkenyl or C2-C7alkinyl optionally substituted by C3-C6cycloalkyl, phenyl, pyridyl, C1-C3alkoxy; R2 represents hydrogen; -NH2; C2H5O-, substituted C1-C5alkyl specified in -CH2OH, -CH2-NH2, -CH=CH2, -CH=CHCl, -C=CH, -CH2F, -CHF2, -CF3, -CH2CF3, cyclo-C3H7, -CF2CF2CF2CF3, -CF2CF2CF2CHF2, -CH2CF2CF2CF2CF3.

Pharmaceutical composition containing pyrazine derivative and method for using pyrazine derivative in combination / 2463051
Invention refers to a pharmaceutical combination and to its use for treating an infection caused by influenza virus. The declared composition contains a pyrazine derivative of formula wherein R1 and R2 are identical or different, and each represents a hydrogen atom or a halogen atom; and R3 represent a hydrogen atom or a protective group for amino group or its salt, and, and a neuraminidase inhibitor. The neuraminidase inhibitor is specified in oseltamivir, zanamivir, peramivir or CS-8958.

Method for retrobulbar anaesthesia in vitreoretinal surgeries / 2462278
Invention refers to medicine, namely anaesthiology in ophthalmosurgery, and may be used in vitreoretinal surgeries, including those terminated by the stage of introducing silicone oil. For this purpose, 40-45 minutes before the operation, the retrobulbar introduction of a mixture of 2% lidocaine and 0.75% ropivacaine in proportions 1:1 in the amount of 4-5 ml is prescribed. It is followed by the intraoperative intravenous titration introduction of 0.01% nitroglycerine starting with 1 ml 1-2 minute before the introduction of silicone oil in response to a surgeon's signal. The nitroglycerine introduction is terminated when patient's systolic blood pressure becomes lower than the initial values by 10-20%.

Intermediate antianginal drug / 2460542
Invention refers to an intermediate antianginal drug containing nitroglycerine, glucose, stearic acid and/or calcium or magnesium stearate, ethyl cellulose or microcrystalline cellulose with the nitroglycerine-glucose relation being (2-3):1 in the following proportions, wt %: nitroglycerine 5-15, glucose 58-86, starch 5-15, stearic acid and/or calcium or magnesium stearate 2-7, ethyl cellulose or microcrystalline cellulose 2-5.

Pharmaceutical combinations of angiotensine receptor antagonist and nep inhibitor / 2459809
What is described is a specific combination - [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(valeroyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] trisodium salt pentahydrate in a solid state which is a double-action compound of angiotensin receptor antagonist and NEP inhibitor, a method for preparing it, a pharmaceutical composition and using said combination for hypertension and cardiac failure.

$Method of optimising conditions of knitting of fractions of extremity bones and their consequences in conditions of their immobilisation$ Method of optimising conditions of knitting of fractions of extremity bones and their consequences in conditions of their immobilisation / 2454962
Invention relates to medicine, namely, to traumatology and orthopedics, and can be applied for optimisation of knitting of extremity bones in case of fractures, unknitted fractures or false joints. For this purpose realised is stable osteosynthesis, which includes reposition of bone fragments and their stable immobilisation. After that on 8 - 10 day after operation into the area of bone defect introduced is nitroglycerine in dose to 10 mg, diluted in 2 ml of physiological solution. Immobilisation of bones of damaged segment is preserved until their complete consolidation.

Oxymethyluracyl and mebeverine hydrochloride pill for functional gastrointestinal diseases / 2453308
Invention refers to medicine. The presented therapeutic agent in the form of a pill contains oxymethyluracyl and mebeverine hydrochloride as active substances, as core-coating excipients - mixed potato starch and lactic sugar in relation 1:1; mixed 5% alcohol-acetone acetyl phthalylcellulose (APC), 10% aqueous potato starch and 0.1% aqueous styrene maleic anhydride copolymer (SMAC) in relation 1:1:1 as a humidifier 1; mixed 3% aqueous Kollidon 90F, povidone and 0.1% aqueous SMAC in relation 1:1 as a humidifier 2; 5% APC as a humidifier 3; mixed 64% sugar syrup and 1% Kollidon 25 in relation 5:1 as a humidifier 4 in certain proportions.

Bicyclic gamma amino acid derivative / 2446148
Invention refers to a compound of general formula (I), in the form of optical isomers or their mixtures, and its pharmaceutically acceptable salt, which show activity as α2δ ligand and affinity to a subunit of α2δ potential-dependent calcium channels. In formula each R1, R2, R2', R4, R5, R8 and R8' independently represents hydrogen atom, halogen atom or C1-C6 alkyl group; each R6 and R7 independently represents hydrogen atom or C1-C6 alkyl group; or R2 and R2' together with carbon atom whereto attached form C3-C7 cycloalkyl group; R3 represents hydrogen atom, C1-C6 alkyl group, C1-C6 alkylhalogenide group, C1-C6 alkoxy-C1-C6 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, C1-C6 alkylsulphanyl-C1-C6 alkyl group, C2-C7 acyloxy-C1-C6 alkyl group or C3-C7 cycloalkyl group.

Complex for treating poisonings containing phenothiazine compound and method of treating poisonings / 2445954
Invention refers to medicine and describes a pharmaceutical complex for correcting metabolic disorders in patients suffered from toxic poisonings, containing a phenothiazine compound being methylene blue, a nitrate ester compound being nitroglycerin, ethanol and a pharmaceutically acceptable carrier. Also, there are described methods of treating flouroacetate, ethylene glycol and cyanide poisoning involving introducing an effective amount of the declared complex into a patient in need thereof.

Periphery blood circulation improving remedy / 2246934
Invention provides topical blood circulation improving remedy containing simultaneously nitroglycerine and aminophylline. Remedy can be provided in the form of emulsion, gel, or ointment, which are administered 1-2 times a day.